New marburg vaccine shows promise in early human trial

NCT ID NCT06265012

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a new vaccine called PHV01 against Marburg virus, a rare but severe disease. 36 healthy adults received either the vaccine or a placebo to check safety and immune response. The study aims to find a safe dose and see if the vaccine triggers antibodies against the virus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Marburg virus vaccine (PHV01)
What this could lead to
If successful, this could lead to a safe and effective vaccine to prevent Marburg virus disease, a rare but often fatal illness.
What could go wrong
This is an early Phase 1 trial with only 36 people, so results may not apply to larger populations. The vaccine may not produce a strong enough immune response or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

36 people

The number who actually took part.

Started

Feb 2024

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy, adult, male or non-pregnant, non-lactating females, age 18-60 years * Given written informed consent * No clinically significant health problems * Negative test for SARS-CoV-2 * Agree to avoid conception through Day 29 * Agree to minimize blood and body fluid exposures to others after vaccination through Day 29 * Agree to avoid exposure to immunocompromised persons after vaccination through Day 29 Exclusion Criteria: * Prior infection with Marburg virus, related filovirus, or Ebola virus * Prior infection with vesicular stomatitis virus (VSV) * Received any VSV-vectored vaccine * BMI of ≥ 35 * Household contact who is immunodeficient, or on immunosuppressive medication * Hepatitis B, hepatitis C, HIV-1, HIV-2, history of long COVID, diabetes, atopic dermatitis (eczema), chronic inflammatory disease, autoimmune or autoinflammatory disorder, malignancy, chronic or active neurologic disorder * History of severe reactions to any vaccine or history of severe allergies * Receipt of investigational product up to 30 days prior to randomization * Receipt of licensed or authorized non-live vaccines within 14 days of planned study immunization (30 days for live vaccines). * Known allergy to components of PHV01 * Injection sites obscured by tattoos or physical condition * Significant psychiatric or medical condition or laboratory abnormality on screening * History of Guillain Barre Syndrome or any chronic or acute neurological disorder * Alcohol or illicit drug abuse within past 5 years * Pregnant or lactating female * Administration of blood or IgG within 60 days preceding study * Administration of systemic chronic immunosuppressants (defined as more than 14 days) or other immune modifying drugs within 6 months of study entry * History of blood donation within 60 days of study * Unwilling to undergo diagnostic evaluation of rash (skin biopsy, if indicated) or joint symptoms (arthrocentesis if indicated by joint effusion), in both cases if acceptable to subject * Elective surgery planned during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Marburg virus disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CenExel RCA

    Hollywood, Florida, 33024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.